Revolutionizing Patient Care: 9th City Clinical Hospital Collaborates with ViroGates for Advanced Disease Detection
Tue Jul 31 2018
In a groundbreaking move, the 9th City Clinical Hospital in Minsk has teamed up with ViroGates, a trailblazing medical diagnostics firm. This partnership introduces the hospital’s routine to suPARnostic® Quick Triage, a transformative tool that revolutionizes the detection and assessment of Chronic Kidney Disease (CKD) and sepsis.
As the largest kidney transplant center in Eastern Europe, the hospital performs an impressive 200 kidney transplants every year. By adopting suPARnostic®, the hospital aims to enhance patient care by empowering healthcare professionals to make informed decisions about treatments.
suPARnostic® Quick Triage holds the promise of reshaping disease detection and severity assessment. This partnership represents a significant step forward in accurately and promptly identifying CKD and sepsis, ultimately leading to improved patient outcomes. The hospital’s dedication to medical progress and patient well-being is evident through this collaboration.
In conclusion, the alliance between the 9th City Clinical Hospital and ViroGates propels the field of medical diagnostics to new heights. Through the integration of suPARnostic® into their routine, the hospital sets new standards for patient care and instills hope in individuals affected by CKD and sepsis.
Doctors O. Rummo (Director of the Republican Center for Organ Transplantation) and A. Kalachyk (Head of Nephrology and Renal Replacement Therapy Unit) from the 9th City Hospital Minsk state:
“We are pleased to inform that the detection of soluble urokinase plasminogen activating receptor (suPAR) (commercial kit suparnostic® Quick Triage, produced by ViroGates, Denmark) has been implemented in our routine clinical practice.
Based on the literature we strongly believe that suPAR is the robust and earliest biomarker of CKD progression but also can be used as a new prognostic biomarker in kidney transplant recipient (for example in FSGS recurrence) and patients with sepsis.
We also declare that it will be used at our hospital for routine clinical decision making but at the same time as the largest kidney transplant center in the Eastern Europe (with up to 200 kidney transplant cases per year) we continue to investigate the predictive value of suPAR in different clinical situation after kidney transplantation and will drive our own study for it.”
